Evidence map›Paper›PMID 10931149›Full record

ArticleClinical and experimental immunology2000

Expression of MHC class II in T cells is associated with increased HIV-1 expression.

M Saifuddin, G T Spear, C Chang, K A Roebuck

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in Clinical and experimental immunology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

M SaifuddinDepartment of Immunology/Microbiology, Rush University, Chicago, IL, USA. msaifudd@rush.edu
G T Spear
C Chang
K A Roebuck
Rush University · USUniversity of Michigan–Ann Arbor · US

Funding

INTERACTION OF HIV-1 WITH COMPLEMENTR01AI031812 · NIAID · RUSH UNIVERSITY MEDICAL CENTER · PI SPEAR, GREGORY T · 1996 to 1998
–
INTERACTION OF HIV-1 WITH COMPLEMENTR29AI031812 · NIAID · RUSH UNIVERSITY MEDICAL CENTER · PI SPEAR, GREGORY T · 1991 to 1995
–
NIAID NIH HHS AI 31812
6 · The paper itself

Abstract

HIV-1 replicates in activated T cells at significantly higher levels than in resting cells. Thus, certain molecules up-regulated during T cell activation appear to be important for HIV-1 replication. In this study, we present evidence suggesting that expression of MHC class II (class II) molecules on CD4+ T cells facilitate HIV-1 replication. T cells that expressed class II supported greater virus replication than T cells lacking class II. The class II+ cells, when either infected with HIV-1 or transfected with an env-minus HIV-1 provirus plasmid, produced 10-20-fold greater virus expression than class II- cells. Anti-class II antibody markedly inhibited virus expression in class II+ cells (but not class II- cells) and also decreased the nuclear binding activity of AP-1, an inducible transcription factor important in T cell activation and HIV-1 expression. Most importantly, the induction of class II expression by transfection of the MHC class II transactivator (CIITA) stimulated HIV-1 replication in Jurkat T cells. Taken together, these data suggest that expression of MHC class II molecules and/or CIITA in T cells enhances HIV-1 transcription.

Indexed as

Virus ReplicationCD4-Positive T-LymphocytesCell LineChemokinesCulture Media, ConditionedCytokinesGenes, ReporterHIV-1HLA-DR AntigensHumansJurkat CellsLymphocyte ActivationProvirusesTranscription Factor AP-1TransfectionChemokinesCulture Media, ConditionedCytokinesHLA-DR AntigensTranscription Factor AP-1

Identifiers

PMID10931149
PMCPMC1905707
OpenAlexW2059765404

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.